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Abstract
Genome-wide association studies (GWAS) have yielded novel genetic loci underlying common diseases. We propose a
systems genetics approach to utilize these discoveries for better understanding of the genetic architecture of rheumatoid
arthritis (RA). Current evidence of genetic associations with RA was sought through PubMed and the NHGRI GWAS catalog.
The associations of 15 single nucleotide polymorphisms and HLA-DRB1 alleles were confirmed in 1,287 cases and 1,500
controls of Japanese subjects. Among these, HLA-DRB1 alleles and eight SNPs showed significant associations and all but
one of the variants had the same direction of effect as identified in the previous studies, indicating that the genetic risk
factors underlying RA are shared across populations. By receiver operating characteristic curve analysis, the area under the
curve (AUC) for the genetic risk score based on the selected variants was 68.4%. For seropositive RA patients only, the AUC
improved to 70.9%, indicating good but suboptimal predictive ability. A simulation study shows that more than 200
additional loci with similar effect size as recent GWAS findings or 20 rare variants with intermediate effects are needed to
achieve AUC=80.0%. We performed the random walk with restart (RWR) algorithm to prioritize genes for future mapping
studies. The performance of the algorithm was confirmed by leave-one-out cross-validation. The RWR algorithm pointed to
ZAP70 in the first rank, in which mutation causes RA-like autoimmune arthritis in mice. By applying the hierarchical
clustering method to a subnetwork comprising RA-associated genes and top-ranked genes by the RWR, we found three
functional modules relevant to RA etiology: ‘‘leukocyte activation and differentiation’’, ‘‘pattern-recognition receptor
signaling pathway’’, and ‘‘chemokines and their receptors’’. These results suggest that the systems genetics approach is
useful to find directions of future mapping strategies to illuminate biological pathways.
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Introduction
Genome-wide association studies (GWAS) have identified a
large number of novel genetic loci underlying susceptibility to
common diseases [1], which leads to an interest in how these
discoveries may be translated into improvement in health care and
public health. Identification of associated variants can illuminate
causal pathways and provide a clue for therapeutic targets [2].
Ultimately, it may be possible to predict the development of
common diseases by genetic profiling, in which multiple genetic
loci are simultaneously tested [3].
There are conflicting views regarding the usefulness of genetic
variants in disease prediction [4–8]. The idea widely received is
that the predictive ability of genetic profiling is limited with some
exceptions [5] because most common genetic variants identified to
date confer relatively small effects on disease risk and explain a
small portion of the individual variation in disease risks [9]. The
risk estimates will be updated and become more accurate with new
genetic discoveries by conducting more large-scale GWAS [6] and
by extending the analysis of low frequency and rare variants [10].
There are some examples that individually rare variants with
relatively large effect contribute to complex trait variation [11–13].
It is important to infer the allelic architecture of as-yet-discovered
risk variants on the basis of current evidence of known disease-
associated variants in order to provide clues for future mapping
strategies [14].
There are prerequisites for evidence-based genetic testing. First,
a rigorous scientific basis for the genetic variants used for the
genetic profiling is essential [15]. In fact, most of the genetic
variants used by direct-to-consumer genetic testing to predict an
individual’s risk to common diseases have been shown to lack
consistent evidence of gene-disease associations [15]. Second, and
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variants should be evaluated [5]. The predictive ability can be
quantified by several measures such as the area under the receiver
operating characteristic curve [16]. Third, it is necessary to
corroborate the generalizability of a genetic risk prediction model
in independent datasets [17]. Systematic validation and charac-
terization of the evidence of genetic associations at both discovery
and translational phases of human genomics are also required
[18,19]. In these circumstances, meta-analysis can be a useful tool
to improve the estimation of effect sizes of genetic variants by
combining results from individual studies, thereby making it
possible to evaluate variants for model inclusion in a rigorous
way [20].
We propose here a systems genetics approach to utilize current
evidence of genetic associations for better understanding of the
genetic architecture of complex disease [21]. The outline of our
approach is schematically shown in Figure 1 (The left and right
columns correspond to the first three and last steps in the following
description). First, genetic variants associated with the disease of
interest are identified by exhaustively reviewing meta-analyses of
genetic association studies. Second, the association and the
predictive ability of the selected variants are confirmed in real
case-control subjects. Third, a framework of simulation study is
formulated to address how many additional loci should be mapped
for the establishment of acceptable levels of genetic risk prediction.
Fourth, a network analysis is implemented where information on
disease-associated genes are integrated through human inter-
actome such as the protein-protein interaction (PPI) network for
the design of future mapping studies and exploring biological
pathways [22].
We applied the systems genetics approach to rheumatoid
arthritis (RA, [MIM 180300]). RA is a common autoimmune
disease characterized by chronic, destructive and debilitating
arthritis [23]. The etiology of RA is not completely known and
most likely involves a complex interplay of both genetic and
environmental factors. It has been shown that multiple alleles at
the HLA-DRB1 locus within the major histocompatibility complex
(MHC) region are associated with RA. RA susceptibility loci
outside the MHC region have been identified through candidate
gene approaches and GWAS [24,25]. The subdivision of RA
patients in terms of the presence or absence of rheumatoid factor
(RF) and antibodies against cyclic citrullinated peptide (anti-CCP)
is increasingly recognized for possible prevention and treatment
strategies. Genetic factors may also contribute to the phenotypic
diversity in RA [26].
Results
Electronic database searches
We sought published meta-analyses that had evaluated the
association between genetic variants and RA risk in population-
based studies through two electronic databases: PubMed and
NHGRI GWAS catalog. Figure S1A shows the outline of our
literature search strategy using PubMed database. The reasoning
for each of the excluded articles in the abstract reading, full-text
search and data extraction stage is listed in Tables S1, S2, and S3,
respectively. After selecting meta-analyses that fulfilled inclusion
criteria, we found 29 articles addressing 27 variants located on 18
genetic loci [27–55]. After reducing redundant variants on the
same genetic locus, 20 variants were identified (Text S1A). We also
retrieved seven articles addressing the contribution of the HLA-
DRB1 locus [56–62].
In order to overview the retrieved meta-analyses, we classified
individual studies analyzing the same genetic variants into three
groups: studies showing significant evidence of increased and
reduced risk, or non-significant result (Figure 2). In cases of single
nucleotide polymorphism (SNP) rs7574865 at the STAT4 locus,
rs2476601 at the PTPN22 locus, and rs6920220 and rs10499194
at the TNFAIP3-OLIG3 locus, consistent lines of evidence of
associations were observed. In the other cases, more than half of
the individual studies did not show significant evidence of
association. However, the direction of associations in the studies
showing significant evidence was consistent for each variant except
for rs1800629 at TNF-a and rs396991 at FCGR3A. This result
suggests that most of the individual studies may be underpowered
to detect small genetic effect [63,64]. Thus, conclusions derived
from meta-analyses may be useful to select genetic variants for risk
prediction models.
The outline of the NHGRI GWAS catalog search is shown in
Figure S1B. Eight articles were retrieved [52,65–71]. We found
the 61 associations with P,1.0610
25: 7 for the HLA region and
54 for the non-HLA region comprising 34 distinct genetic loci.
Restricting the statistical significance level at P,5.0610
28,1 8
associations, 10 of which did not overlap those from the PubMed
search, were retrieved. All of the retrieved associations were
derived from meta-analyses of several GWAS and replication
studies [69–71].
Re-analysis of published meta-analyses and selection of
genetic variants
We re-analyzed the meta-analyses addressing 20 genetic
associations (Table S4; Text S1A). For each meta-analysis, a
median of 6,758 cases (interquartile range [IQR]: 3,445–10,994)
and 7,643 (IQR: 3,367–14,406) controls had been involved. We
found that there were 10 meta-analyses showing statistically
significant between-study heterogeneity. This indicates that the
between-study heterogeneity was more frequent than what would
be expected by chance (P=7.2610
26). The median of I
2 metric
was 40.4% (IQR: 16.1–63.9%). In 14 of 20 meta-analyses, the
genetic associations passed the significance threshold of P=
2.5610
23 under the fixed effects model meta-analysis in the
overall populations. Even when applying the random effects model
meta-analysis, which is a conservative approach under the
presence of between-study heterogeneity, evidence of association
was confirmed in all of the 14 polymorphisms (P,0.05).
From the PubMed search, we identified the following 14
variants that fulfilled our selection criteria: rs7574865 (STAT4);
rs3087243 (CTLA4); rs7528684 (FCRL3); rs3761847 (TRAF1-
C5); rs2812378 (CCL21); rs4810485 (CD40); rs42041 (CDK6);
rs2240340 (PADI4); rs2476601 (PTPN22); rs2073838 (SLC22A4);
rs2004640 (IRF5); rs6920220 and rs10499194 (TNFAIP3-OLIG3);
and rs333 (CCR5). Among these 14 polymorphisms, 13 were SNPs
and one was the 32 bp-deletion polymorphism in CCR5 (referred
to as rs333).
For the HLA-DRB1 alleles, we selected six alleles that were
significantly associated with RA risk in a comprehensive review
article [62] using the largest collection of relevant articles: HLA-
DRB1*01:01, DRB1*09:01, DRB1*10:01, DRB1*04:04, DRB1*04:01,
and DRB1*04:05.
We identified an additional 10 SNPs from the NHGRI GWAS
catalog: rs3093024 (CCR6); rs874040 (RBPJ); rs11676922 (AFF3);
rs13017599 (REL); rs6859219 (ANKRD55); rs934734 (SPRED2);
rs2736340 (BLK); rs26232 (C5orf30); rs13315591 (FAM107A); and
rs706778 (IL2RA).
Collectively, 23 SNPs, one deletion polymorphism, and six
HLA-DRB1 alleles that were significantly associated with RA risk
were identified. Allele frequencies of the genetic variants with
validated associations with RA were highly differentiated between
Systems Genetics Approach in Rheumatoid Arthritis
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15 SNPs with minor allele frequency greater than 5% in Japanese
and six HLA-DRB1 alleles were selected through our database
searches.
Ethnic differences
We examined the ethnicity-specific effects of these variants
(Table S6). We found heterogeneity in the odds ratios (ORs)
between ethnic groups at P,0.05 for rs2240340 (PADI4) and
rs7528684 (FCRL3). The OR of rs2240340 was larger for East
Asian (OR=1.31, 95% confidence interval [CI]; 1.22–1.41,
P=5.6610
213) than for European descent populations (OR=
1.03, 95% CI; 0.99–1.07, P=0.16). Similarly, the rs7528684
association was stronger for East Asian populations (OR=1.16,
95% CI; 1.09–1.24, P=7.8610
26) than for European descent
populations (OR=1.03, 95% CI; 0.98–1.09, P=0.27). The effects
observed with East Asian populations were used in the genetic risk
score (Table 1).
Figure 1. The systems genetics approach proposed in this study. A) Databases from which knowledge is extracted. Meta-analyses and GWAS
findings are sought in PubMed and NHGRI GWAS catalog, respectively. Human protein-protein interaction data is obtained from HPRD. B) Retrieved
information is used to create two types of networks: ‘gene-disease association network’ and ‘protein-protein interaction network’. C) The data
analysis phase. The gene-disease associations are confirmed by using real case-control subjects. The predictive ability of selected genetic variants is
evaluated and the result is used in the simulation study to infer allelic architecture of as-yet-discovered genetic variants. Two types of networks are
integrated to prioritize genes by the global measure of distance to known disease-associated genes within the protein-protein interaction network.
Hierarchical clustering algorithm is applied to a subnetwork comprising top-ranked genes and functional annotation for each cluster is used for the
inference on biological pathways underlying the disease of interest. D) The systems genetics approach emerges two types of clues: Future mapping
strategies, and biological pathways.
doi:10.1371/journal.pone.0025389.g001
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We conducted a case-control study of 1,287 RA cases and 1,500
controls in Japanese (see Materials and Methods for description of
our cohort). Genotype counts for six HLA-DRB1 alleles and 15
SNPs are shown in Table S7. For the SNPs, the missing genotype
rates were small (at most 1.3% for rs2736340). SNP rs2004640
(IRF5), which deviated from the HWE in controls at P,0.001, was
excluded from subsequent analyses.
We assessed the association of each genetic variant with RA risk
by logistic regression analysis (Table 1). For the HLA-DRB1 alleles,
HLA-DRB1*04:05 allele showed highly significant evidence of
association with the risk of RA. It should be noted that the ORs of
all the HLA-DRB1 alleles in the multivariate logistic regression
analysis were larger than those in the univariate analysis. When an
allele was evaluated in the univariate analysis, the other five
putative risk alleles were grouped together into one referent group,
which resulted in a weakened association signal.
For the SNPs, strong evidence of association was observed with
rs3093024 in CCR6 (P=4.1610
25, OR=1.25), rs2240340 in
PADI4 (P=1.5610
24, OR=1.23), rs2736340 in BLK (P=
3.2610
24, OR=1.24), and rs4810485 in CD40 (P=4.7610
24,
OR=0.80). We found that four SNPs showed nominally signi-
ficant associations at P,0.05 for rs26232 (C5orf30), rs2073838
(SLC22A4), rs11676922 (AFF3), and rs7528684 (FCRL3). SNPs on
SPRED2 and STAT4 showed suggestive associations at P,0.1.
SNPs on CTLA4, TRAF1-C5, and IL2RA had the same direction of
effect as identified in previous studies. SNP rs10499194 on
TNFAIP3-OLIG3 showed the opposite direction of effect. The
observed opposite direction of rs10499194 seems to be attributable
to the difference in linkage disequilibrium between marker and
true disease allele across populations. Shimane et al. showed a
similar result and identified a non-synonymous SNP (rs2230926) in
TNFAIP3 associated with RA [72].
The ORs for SNPs obtained with the univariate analysis were
similar to those with the multivariate analysis, indicating that the
associations of these SNPs are independent association signals.
These results suggest that a substantial proportion of the loci
identified in the meta-analyses are likely to be shared across
populations.
Discrimination using genetic risk models
This study is reported in accordance with the Strengthening the
Reporting of Genetic Risk Prediction Studies recommendations
[73]. With the use of the receiver operating characteristic (ROC)
curve, we calculated the area under the ROC curve (AUC) to
evaluate the predictive ability of the genetic risk scores based on
the selected variants (see Materials and Method for description of
the construction of genetic risk score). The AUC for the HLA
model was 65.9% (95% CI, 63.9 to 67.9%). The non-HLA model
including 14 SNPs showed an AUC of 58.8% (56.6 to 60.9%). The
AUC for the integrative model was 68.4% (66.4 to 70.4%). The
addition of 14 SNPs to the HLA-DRB1 alleles increased the AUC
by 2.5%. The observed increase in the AUC was statistically
significant (P=2.8610
26). The integrative model shows better fit
than the HLA model in terms of Akaike’s information criterion
(Table 2). We examined an ad hoc model, where rs10499194 on
Figure 2. Overview of association studies in RA of 20 genetic variants examined in the meta-analyses met our inclusion criteria.
Colored bars displays number of individual studies according to the result of testing for association of each variant with RA: red, studies show
significant evidence of an increased risk; blue, studies show significant evidence of disease protection; and green, studies show non-significant result.
The significance level was set at P=0.05.
doi:10.1371/journal.pone.0025389.g002
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previous studies was removed. The AUC was then 68.6 (66.6 to
70.6%). The improvement in the AUC from the integrative model
was statistically significant (P=0.034).
We performed the same ROC analyses by using only the
patients with both anti-CCP and RF positivity (Table 2). The
AUC for the HLA, non-HLA and integrative models was 68.3%
(65.2 to 71.4%), 60.0% (56.7 to 63.3%), and 70.9% (67.8 to
73.9%), respectively. For each genetic risk model, the AUC in
both RF and anti-CCP positive patients versus controls was
greater than that in overall patients versus controls. The result of
the association study for anti-CCP and RF positive RA is shown in
Table S8.
Figure 3 depicts the distribution of genetic risk scores by
phenotypic status for the integrative model. The distribution of the
genetic risk scores in cases differs from that in controls
(P=1.1610
261). The curve in RF and anti-CCP positive cases
shifts upward compared to the curve in overall cases, indicating
that the risk scores in RF and anti-CCP positive cases were larger
than those in overall cases. This was reflected in better
discrimination ability between both RF and anti-CCP positive
patients and controls (AUC=70.9%) than that between overall
cases and controls (AUC=68.4%). Each curve in Figure 3 looks
like multimodal distribution. The multimodality of these curves is
attributable to differences in genetic risk score among the HLA-
DRB1 genotypes.






OR (95% CI) P OR (95% CI) P OR (95% CI)
HLA-DRB1 *01:01 +/2 1.29 (1.03–1.61) 0.025 1.95 (1.52–2.48) 8.8610
28 1.60 (1.39–1.84)
*09:01 +/2 1.20 (1.04–1.39) 0.012 1.74 (1.48–2.04) 1.8610
211 1.67 (1.44–1.94)
*10:01 +/2 2.88 (1.42–5.83) 3.3610
23 3.59 (1.72–7.52) 7.0610
24 2.35 (1.90–2.91)
*04:01 +/2 1.89 (1.23–2.90) 3.9610
23 2.70 (1.69–4.30) 3.0610
25 3.30 (3.01–3.61)
*04:04 +/2 1.49 (0.55–4.02) 0.43 2.92 (0.98–8.67) 0.054 1.85 (1.54–2.22)
*04:05 +/2 2.31 (2.01–2.66) 1.3610
231 2.80 (2.40–3.27) 9.4610
239 3.84 (3.30–4.46)
SNPs with strong evidence of association (P,2.5610
23)
CCR6 rs3093024 A/G 1.25 (1.12–1.39) 4.1610
25 1.26 (1.13–1.42) 6.3610
25 1.19 (1.15–1.24)
PADI4 rs2240340 T/C 1.23 (1.11–1.37) 1.5610
24 1.24 (1.11–1.40) 2.6610
24 1.31 (1.22–1.41)
BLK rs2736340 T/C 1.24 (1.10–1.39) 3.2610
24 1.24 (1.09–1.41) 7.8610
24 1.19 (1.13–1.27)
CD40 rs4810485 T/G 0.80 (0.72–0.89) 4.7610
24 0.82 (0.73–0.92) 7.8610
24 0.87 (0.83–0.90)
SNPs with nominally significant association signals (P,0.05)
C5orf30 rs26232 T/C 0.86 (0.77–0.98) 0.018 0.86 (0.75–0.98) 0.021 0.90 (0.87–0.94)
SLC22A4 rs2073838 A/G 1.14 (1.02–1.27) 0.022 1.17 (1.04–1.32) 0.012 1.11 (1.05–1.18)
AFF3 rs11676922 T/A 1.11 (1.00–1.24) 0.043 1.11 (0.99–1.24) 0.083 1.14 (1.10–1.18)
FCRL3 rs7528684 G/A 1.11 (1.00–1.24) 0.047 1.08 (0.96–1.21) 0.20 1.16 (1.09–1.24)
SNPs showing the same direction of effect
SPRED2 rs934734 G/A 1.14 (0.99–1.31) 0.064 1.17 (1.00–1.36) 0.043 1.13 (1.09–1.17)
STAT4 rs7574865 T/G 1.10 (0.98–1.23) 0.093 1.09 (0.97–1.23) 0.14 1.23 (1.19–1.27)
CTLA4 rs3087243 A/G 0.92 (0.82–1.04) 0.18 0.96 (0.84–1.10) 0.56 0.89 (0.85–0.95)
TRAF1 rs3761847 A/G 1.05 (0.95–1.17) 0.35 1.03 (0.91–1.15) 0.66 1.13 (1.09–1.17)
IL2RA rs706778 T/C 1.05 (0.95–1.17) 0.36 1.05 (0.93–1.17) 0.43 1.12 (1.09–1.16)
SNPs showing the opposite direction of effect
TNFAIP3 rs10499194 T/C 1.18 (0.96–1.46) 0.11 1.18 (0.94–1.48) 0.15 0.82 (0.77–0.87)
AA1 and A2 represent the coded and non-coded alleles, respectively.
BORs and 95% CIs were estimated by logistic regression analyses using univariate analysis for each allele and then using multivariate analysis including all the alleles. The
number of coded alleles (A1) was used as the predictor value in the logistic regression analyses.
CORs and 95% CIs were calculated by meta-analyses of published studies: HLA-DRB1 from [62]; CD40, SLC22A4, STAT4, CTLA4, TRAF1, TNFAIP3, and IRF5 from re-analysis of
meta-analyses shown in Table S4; PADI4 and FCRL3 from re-analysis of ethnicity-specific meta-analyses shown in Table S6; and CCR6, BLK, C5orf30, AFF3, SPRED2,a n d
IL2RA from original GWASs [69–71]. These ORs were used to create genetic risk scores.
doi:10.1371/journal.pone.0025389.t001
Table 2. The discriminative ability and the global model fit of
three predictive models according to subphenotype of case
patients.
Case phenotype Model AUC (95% CI) AIC
A
Overall HLA 65.9 (63.9–67.9) 3477.7
Non-HLA 58.8 (56.6–60.9) 3630.7
Integrative 68.4 (66.4–70.4) 3421.9
RF & anti-CCP positive HLA 68.3 (65.2–71.4) 1603.7
Non-HLA 60.0 (56.7–63.3) 1694.2
Integrative 70.9 (67.8–73.9) 1578.0
AAkaike’s information criterion.
doi:10.1371/journal.pone.0025389.t002
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mapped?
We investigated how many additional loci are required to
achieve an acceptable level of genetic risk prediction via simulation
study. We set AUC of 80.0% as an acceptable level based on the
diagnostic accuracy of anti-CCP antibody and RF for RA.
According to a recent meta-analysis [74], the pooled sensitivity
and specificity were 67% and 95% for anti-CCP antibody,
respectively, and 69% and 85% for IgM RF, respectively. The
naı ¨ve estimate of the AUC was 81% for anti-CCP antibody and
75% for IgM RF.
We simulated the distribution of RA risks in the general
population based on observed ORs and allele frequencies for the
selected variants (see Materials and Methods, and Text S1B for
details). For the base model in which 13,392,312 multi-locus
genotypes generated by combining the six HLA-DRB1 alleles and
the 14 SNPs are included, the simulated AUC was 71.0%. The
AUC of the base model was similar to that observed in anti-CCP
and RF positive patients (AUC=70.9%). Starting with the base
model, we evaluated the simulated AUC value assuming that
hypothetical additional loci were discovered.
Result of the simulation study is shown in Figure 4. Under the
common disease-common variant hypothesis, ,50 loci are needed
in the setting of additional loci with OR=1.2 and risk allele
frequency (RAF) of 0.30. Taking into consideration the fact that
the ORs from recent GWAS of RA were close to 1.1, a scenario of
OR=1.1 and RAF=0.30 may be more realistic. In this scenario,
,220 loci are required. When assuming the multiple rare variants
with intermediate effects that remain undiscovered and setting the
additional loci with OR of 3.0 and RAF of 0.01, only ,20 loci are
sufficient for AUC of 0.80. When assuming OR=2.0 and
RAF=0.01, an additional 50 loci are needed.
We further implemented simulations in which combination of
common and rare variants was examined. When assuming HLA-
DRB1 alleles, 150 loci with OR=1.1 and RAF=0.30, and 10 loci
with OR=3.0 and RAF=0.01, the AUC was 80.2%. The
simulation rendered AUC=95.2% under the assumption of HLA-
DRB1 alleles, 300 loci with OR=1.1 and RAF=0.30, and 140
loci with OR=3.0 and RAF=0.01.
Network analysis
The simulation study shows that many additional variants need
to be discovered. We hypothesized that variants within genes on
the same biological pathways of known RA susceptibility genes can
be associated with RA. Then, we performed following network
analyses to prioritize genes for future mapping studies.
We constructed the PPI network by using HPRD database
[75,76]. The PPI network contained 37,080 interactions between
9,521 human proteins. The selected variants were assigned to a
single protein-coding gene (Table S5; Text S1C). There are 19
RA-associated proteins mapped in the PPI network (HLA-DRB1,
STAT4, FCRL3, TRAF1, CCL21, CD40, CDK6, PTPN22,
SLC22A4, IRF5, CTLA4, TNFAIP3, CCR6, REL, SPRED2,
BLK, FAM107A, and IL2RA).
We used the random walk with restart (RWR) algorithm [77] to
prioritize genes in terms of the proximity to the validated RA
susceptibility genes within the PPI network (see Materials and
Method for details). As a preliminary test, we confirmed that the
value of restart probability, r, did not largely affect the ranking of
genes. When we examined different values of r (0.3, 0.5, and 0.7),
Figure 3. Distribution of risk scores by phenotypic status for the integrative model, in which six HLA-DRB1 alleles and 14 SNPs were
included. The curves were generated with a Gaussian kernel density smoother.
doi:10.1371/journal.pone.0025389.g003
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0.993. The predictive ability of the network-guided gene
prioritization method was evaluated by the leave-one-out cross-
validation. As shown in Figure 5, most of the left-out genes are
highly evaluated. For example, TRAF1 ranked 58th among 9,503
genes evaluated. The AUC by the leave-one-out cross-validation
was 84.4%, indicating an excellent predictive ability. This result
also suggests that the RA-associated genes are in proximity to each
other within the PPI network.
In the top-ranked genes, we can find many genes that may be
involved in the susceptibility to RA and other autoimmune diseases.
The RWR algorithm points to ZAP70 in the first rank. Notably, a
mutation in ZAP70 is identified to cause chronic autoimmune
arthritis in mice [78]. Sakaguchi et al. [78] demonstrate that the
mutation in the mouse ZAP70 affects thymic T-cell selection and
leads to the development of RA-like arthritis. ZAP70 has direct
interactions with PTPN22 and FCRL3 among proteins encoded by
RA-associated genes in the HPRD database. FCRL3 has a direct
interaction only with ZAP70 in the HPRD database, which might
cause upward bias in the ranking of ZAP70. Even when excluding
FCRL3 from the list of seed vertices, ZAP70 ranked 42th among
9,503 genes, indicating that the priority of the gene is robust and
that ZAP70 is located proximal to proteins encoded by the RA-
associated genes in the PPI network. We found that CD247, IL2RB
and IL2 ranked 32th, 34th and 39th, respectively, and have been
associated with RA in follow-up study of GWAS [79,80] and studies
exploring shared susceptibility loci among autoimmune diseases
[81,82]. CD80, FCGR2A, FCGR2B, ICAM1, JAK2, LYN, NFKBIA,
PTPN11, STAT3 and TRAF3IP2 were shown to be associated with
other autoimmune diseases according to the NHGRI GWAS
catalog and systematic review [83].
Figure 6A depicts an RA-associated network that is a
subnetwork of the PPI network in which vertices are the RA-
associated genes and genes ranked in the top 100 by the RWR
algorithm and edges are physical interactions between their
products. In order to detect functional modules in the RA-
associated network, we applied the EAGLE algorithm [84] and
found three complexes each containing more than 10 vertices
(referred to as CL1-3). The CL1 and CL2 overlap each other.
We further explored functional annotations of these three
clusters by using DAVID [85,86] (Table 3). The three clusters
fitted into different categories of immunological pathway. CL1 can
be assigned to an immunological pathway ‘‘leukocyte activation
and differentiation’’ according to Gene Ontology (GO) terms
annotated to genes in CL1 (Figure 6B). CL2 is associated with
‘‘pattern-recognition receptor signaling pathways’’ since genes in
CL2 are enriched for GO terms and KEGG pathways such as
Toll-like receptor and Nod-like receptor signaling pathways
(Figure 6C). CL3 is enriched for genes relevant to ‘‘chemokines
and their receptors’’ (Figure 6D). This result shows that the
exploration of topology of the network based on curated disease
susceptibility genes is useful to find functional modules involved in
disease pathology. We confirmed that similar biological pathways
are observed when the number of top ranked genes included into
the RA-associated network is altered to 50 and 150 (Figures S2,
S3, Tables S9, S10).
Discussion
The phenomenon named ‘missing heritability’ has received
much attention [9] and calls into substantive question the
usefulness of genetic profiles for disease risk prediction. In this
Figure 4. Simulation study addressing how many additional loci should be mapped for the establishment of excellent genetic risk
prediction. Five scenarios with different combination of OR and RAF were examined.
doi:10.1371/journal.pone.0025389.g004
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validate current evidence of genetic associations with RA and
utilized them to find directions of future mapping strategies.
One fundamental question is whether genetic risk factors for RA
overlap across ethnic groups [87]. Although the associations of two
SNPs (PADI4 and FCRL3) were significantly stronger in East
Asian than in European, these two SNPs represented significant
association in the overall populations and the recent European
GWA meta-analysis [70] captured weak association signals of
these SNPs. This suggests that these SNPs may be common risk
factors but that their contribution to RA risk may differ across
ethnic groups. Furthermore, we confirmed that most of the
selected genetic variants from meta-analyses and NHGRI GWAS
catalog were consistently replicated in a case-control study of
1,287 RA cases and 1,500 controls of Japanese. These results
suggest that a substantial proportion of the loci identified in the
meta-analyses are likely to be shared across populations.
The predictive ability of genetic variants for the development of
RA was moderate: the AUC for the integrative model was 68.4%
(66.4 to 70.4%). Notably, the AUC improved to 70.9% (67.8 to
73.9%) when we used patients with both RF and anti-CCP
positivity. This finding is consistent with European study
(AUC=71% [68 to 73%] for anti-CCP positive RA) although
the list of selected variants used was slightly different [88]. This is
the first study showing that the predictive ability of genetic variants
for RA mainly derived from European GWAS is similar between
European and non-European populations by using a substantial
number of case and control subjects. However, the predictive
ability is suboptimal at the current stage.
When we implemented a simulation study addressing how
many additional loci should be mapped, we set a goal of genetic
risk prediction that achieves a similar level of accuracy with anti-
CCP antibody for RA. Such genetic risk prediction may have
clinical utility: when patients have primary symptoms such as joint
pain and stiffness, prior knowledge of their higher genetic risks for
RA may inspire them to undergo highly specific diagnostic tests
such as anti-CCP antibody. Early detection and treatment can
prevent severe disability for many patients.
According to the simulation study, more than 200 loci with
OR=1.1 and RAF=0.30 are required to achieve AUC of 80.0%,
implying that efforts relying only on GWAS may be reaching
limits for improving predictive ability. With the advent of the
development of massively parallel DNA sequencing technologies,
exploring rare variants of large effect has attracted increased
attention [89]. There is some evidence of rare variants with a large
impact on risk of RA and autoimmune diseases [13,90,91].
Functionally defective rare variants in SIAE were recently shown
to be associated with autoimmune diseases including RA with ORs
estimated at approximately 8.0 [91]. In our simulation study,
additional 20 rare but not private variants (minor allele frequency
of 1%) with intermediate effect (OR of 3.0) suffice for AUC of
80.0%. Several hundreds of cases and controls must be
resequenced for the discovery of such rare variants. However,
whole-genome and whole-exome sequencing of large samples are
costly and otherwise infeasible. The use of bar-coded multiplexed
and target enrichment sequencing of the exonic regions of
hundreds of candidate genes [92,93] could be an alternative
strategy if appropriate candidate genes were selected.
We applied the RWR algorithm to prioritize genes by using
information on the list of curated RA-associated genes and the PPI
network from HPRD database. The predictive ability of the RWR
algorithm was proved to be excellent based on the leave-one-out
Figure 5. ROC curve using the leave-one-out cross-validation method to evaluate the predictive ability of the RWR algorithm. The
gray diagonal line corresponds to the AUC of 0.5 and no discrimination (i.e., random performance).
doi:10.1371/journal.pone.0025389.g005
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PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e25389Figure 6. RA-associated network. A) Entire RA-associated network comprising known RA-associated genes and genes ranked in the top 100 by the
RWR algorithm and edges are physical interactions between their products. Nodes are color coded by hierarchical clusters detected by the EAGLE
algorithm: CL1, red; CL2; cyan, andCL3, yellow. Overlapped region between CL1 and CL2 arerendered in green. Node size is based on the ranking in the
RWR algorithm. Official gene symbols are shown for known RA-associated genes. B–D) Subnetworks corresponds to the hierarchical clusters CL1-3.
doi:10.1371/journal.pone.0025389.g006
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=84.4%). This result suggests that the RA-associated genes are
in proximity to each other within the PPI network, which is
consistent with the recent study showing that the products of RA-
associated genes are more interconnected than would be expected
by chance [94]. The top-ranked genes with the RWR algorithm
are intriguing. The gene in the first position (ZAP70) is a causal
gene of RA-like autoimmune arthritis in mice [78]. Furthermore,
recessive and compound heterozygous mutations in ZAP70 cause
human severe combined immunodeficiency [95–97]. Within the
top 100 ranked genes, genes implicating susceptibility to RA
(CD247, IL2RB and IL2) and to other autoimmune diseases (CD80,
FCGR2A, FCGR2B, ICAM1, JAK2, LYN, NFKBIA, PTPN11, STAT3
and TRAF3IP2) are enriched.
We also found that the analysis of network topology was useful
to find functional modules involved in the disease pathology. This
method has two steps: first, a disease-related network comprising
genes in the vicinity to curated susceptibility genes within the PPI
network is constructed using the RWR algorithm. Second, the
overlapping and hierarchical structure of the disease-related
network is explored and functional annotation is implemented
for each cluster. The systems genetics approach proposed here will
be applicable to most common diseases and will work well
especially when genes associated with the disease of interest are in
proximity to each other within the PPI network. When applying
the method to RA, the resulting clusters were fitted into different
categories of immunological pathways.
CL1 is related to ‘‘leukocyte activation and differentiation’’
(Figure 6B, Table 3). T-cell differentiation plays an important role
in autoimmunity. Strongly self-reactive T cells are primarily
eliminated in the thymus by negative selection (central tolerance).
Some of the self-reactive T cells, however, may escape from
negative selection and can cause autoimmune diseases. Defect in
thymic T-cell selection due to a mutation of Zap70 causes
autoimmune arthritis in mice [78]. CL2 fits into ‘‘pattern-
recognition receptor signaling pathways’’ (Figure 6C, Table 3).
The innate immune functions of macrophages and neutrophils
depend on pattern-recognition receptors such as Toll-like
receptors and Nod-like receptors. Genes relevant to these
pattern-recognition receptor signaling pathways were enriched in
CL2. CL3 corresponds to ‘‘chemokines and their receptors’’
(Figure 6D, Table 3). The main function shared by chemokines
and chemokine receptors is leukocyte chemotaxis, which helps
direct migration of leukocytes to an injury site. Genetic defects in
these biological pathways can inappropriately activate immune
cells leading to inflammation and host cell destruction that can
cause autoimmune diseases. Notably, the clusters inferred from
this study are similar to the pathways implicated by Zhernakova
et al. [83], in which genes associated with autoimmune diseases are
grouped into four categories: ‘T cell differentiation’, ‘immune-cell
activation and signaling’, ‘innate immunity and TNF signaling’,
and ‘cytokines and chemokines’.
Some limitations of our study should be noted. Our electronic
database search had been performed a year ago (on June 18 2010).
Continuing efforts to examine whether more updated genetic
findings appear in publication to renew the list of susceptibility
genes to RA is required. By searching for the NHGRI database
deposited after June 18 2010, we found four relevant arti-
cles.[80,98–100] Genetic variants outside the MHC region passing
the genome-wide significant threshold (5.0610
28) were retrieved.







GO:0045321 Leukocyte activation 20 40.0 23.3 1.4610
221
GO:0002521 Leukocyte differentiation 15 30.0 32.3 8.0610
218
hsa04660 T cell receptor signaling pathway 15 30.0 15.7 1.1610
213
GO:0006468 Protein amino acid phosphorylation 19 38.0 8.0 2.8610
212
Cluster 2
hsa04620 Toll-like receptor signaling pathway 20 40.0 18.2 2.0610
220
hsa04622 RIG-I-like receptor signaling pathway 14 28.0 21.7 7.5610
215
GO:0007249 I-kappaB kinase/NF-kappaB cascade 12 24.0 31.6 4.3610
214
hsa05200 Pathways in cancer 20 40.0 5.4 2.0610
210
hsa04623 Cytosolic DNA-sensing pathway 10 20.0 22.0 2.0610
210
hsa04621 NOD-like receptor signaling pathway 11 22.0 15.1 8.7610
210
Cluster 3
GO:0006935 Chemotaxis 9 52.9 47.6 1.9610
212
GO:0007626 Locomotory behavior 9 52.9 27.8 1.5610
210
GO:0006955 Immune response 11 64.7 13.5 2.7610
210
GO:0006952 Defense response 10 58.8 13.7 3.1610
29
GO:0019957 C-C chemokine binding 4 23.5 231.8 4.4610
27
GO:0016493 C-C chemokine receptor activity 4 23.5 231.8 4.4610
27
AWithin each cluster, related terms are not shown to reduce redundancy. Among terms with parent-child relationships, we selected one showing highest significance
enrichment P-value.
BNumber of GO or KEGG category genes in each cluster.
CPercentage of GO or KEGG category genes in each cluster.
DFold Enrichment of genes in each cluster compared to a background list.
doi:10.1371/journal.pone.0025389.t003
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PADI4) [98,99]. European GWAS identified 8 loci as shared
genetic factors between RA and celiac disease [80]. We
reconsidered our network analysis by including newly discovered
loci. We could assign these 10 loci to 8 unique genes: AIRE,
PADI4, TRAF1, STAT4, YDJC, UBASH3A, CD247, and ATXN2.
TRAF1, STAT4, and PADI4 were already included into our model.
YDJC is not deposited in the HPRD database. Thus, 4 genes
(AIRE, UBASH3A, CD247, and ATXN2) were newly included. We
re-examined the RWR algorithm using a total of 23 genes as initial
vertices. The rank correlation in genes between before and after
including the 4 genes was 0.978. This indicates the ranking of
candidate genes were not largely affected. The result from the
hierarchical clustering method and functional annotation rendered
similar biological pathways (Figure S4, Table S11). As previously
mentioned, CD247 was one of top-ranked genes (32th) in the
original RWR analysis. The result of network analysis by using
additional 4 newly discovered genes converged on the same
biological pathways, suggesting the strong relevance of these
pathways to the etiology of RA. Only physical PPI data were used
to construct the molecular network and it is inevitably noisy and
incomplete. A PPI network integrated with a transcription
profiling network could improve the predictive ability of
network-guided prioritization of genes [22,101].
We have demonstrated that recent successful discoveries of
genetic variants associated with diseases are valuable resources to
provide targets for future resequencing studies to reveal the
biological pathways. Such efforts utilizing GWAS discoveries will
accelerate genetic discoveries and improve the predictive ability of
the genetic variations. While exploration of other types of genomic
variation such as rare and low frequency single nucleotide changes
and insertions and deletions of nucleotides is promising, it may be
challenging because the variants are likely to be population-
specific. The biological pathways highlighted by the various
common genetic variants associated with the disease across
populations will encourage examination and functional annotation
of newly discovered rare variants.
Materials and Methods
Ethics statement
The Ethics Committee of Tokai University approved the study
protocols and all participants gave written informed consent.
Study participants
1,287 RA subjects and 1,500 control subjects of Japanese origin
were recruited. All cases were diagnosed by board certified
rheumatologists and fulfilled 1987 American College of Rheuma-
tology criteria [102]. The dataset was updated from our previous
study [103].
Information on the positivity of anti-CCP and RF for 481 and
462 cases, respectively, was measured. Anti-CCP antibody titers
were measured with the second generation ELISA kit (MESACUP
CCP; Medical & Biological Laboratories Co. Ltd, Nagoya, Japan).
A cut-off value of 4.5 U/ml was used for anti-CCP antibody
positivity. RF positivity was determined by using N-Assay TIA RF
Nittobo (Nitto Boseki Co., Ltd, Koriyama, Japan). The positivity
of anti-CCP and RF was observed in 90.4% and 80.5% cases,
respectively.
Genotyping
All study participants were genotyped for HLA-DRB1 alleles and
selected SNPs described below. Genotyping of HLA-DRB1 alleles
was performed by Luminex Multi-Analyte Profiling system
(xMAP) with a WAKFlow HLA typing kit (Wakunaga, Hiroshima,
Japan). Genotyping of SNPs was performed by TaqMan SNP
Genotyping Assays on the ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems, Tokyo, Japan). Departure
from Hardy-Weinberg equilibrium (HWE) in control samples was
examined at the significance level of P,0.001 by means of the
exact test using PLINK software [104].
Electronic database search strategies
PubMed search. We identified published meta-analyses
addressing the association between genetic variants and RA risk
in population-based studies. We performed a literature search of
the PubMed database (last search June 18, 2010). Searches were
conducted using the following keywords: ‘‘rheumatoid arthritis’’
and [genetic(s) or polymorphism(s) or allele(s) or mutation(s)] and
(meta-analysis or metaanalysis or ‘‘systematic review’’). Reference
mining of retrieved articles was used to identify additional articles.
Meta-analyses included in our analysis had to meet all of the
following criteria: evaluated RA risk as the outcome (analyses of
pharmacogenomics and RA severity were excluded) and published
in English. Two researchers (HN and TC) conducted literature
searches independently, and any disagreement between the two
researchers was accommodated by the third researcher (AT).
Genetic models and methods for combining studies examined in
the retrieved meta-analyses differed according to article. In order
to evaluate evidence of association of genetic variant with RA in
the same statistical manner, we performed re-analysis of published
meta-analyses. Therefore, we included the following meta-
analyses: greater than or equal to five independent studies were
included and the total number of cases and controls was larger
than 3,000; adequate data to calculate OR for each of the included
studies was provided; and per-allele effect of risk allele was
examined. When there were several meta-analyses on the same
variant including different studies, we created a comprehensive set
of individual studies using following criteria: i) studies did not
overlap data between studies, and ii) study with largest sample size
was used when studies overlapped data.
The NHGRI GWAS catalog. Recent update of GWAS
findings was sought by the NHGRI GWAS catalog (http://
www.genome.gov/gwastudies/ Accessed June 18, 2010). We
included the associations that met the genome-wide significance
of P,5.0610
28 in our analysis.
Re-analysis of published meta-analyses and selection of
genetic variants
In the re-analysis of all the retrieved meta-analyses, the per-
allele ORs for individual studies were combined using both fixed
effects model and Dersimonian-Laird random effects model meta-
analyses. We examined the test for association at the significance
level of P,2.5610
23 (=0.05/20) to correct the multiple testing.
Homogeneity across studies was examined by Cochran’s Q test at
the significance level of 0.1. The extent of between-study
heterogeneity was quantified by I
2. I
2 values over 50% indicate
large heterogeneity. All the meta-analyses were performed by
using STATA version 11.0.
We selected genetic variants according to the following criteria:
First, genetic variants showed evidence of association in the re-
analysis of meta-analysis (P,2.5610
23) or in the NHGRI GWAS
catalog (P,0.5610
28). Second, minor allele frequency was larger
than 5% in Japanese as Janssens et al. shows low-frequency genetic
variants with small effects does not largely affect the predictive
ability [105]. The allele frequency in Japanese population was
sought in SNP Control Database [106].
Systems Genetics Approach in Rheumatoid Arthritis
PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e25389In order to introduce possible genetic heterogeneity among
ethnic groups into the risk prediction model, we performed
subgroup analyses in which ORs per ethnic group were estimated.
We used the ethnic group-specific effect into risk prediction model if
meta-analysis fulfilled the following criteria: greater than or equal to
three independent studies were included and the total number of
cases and controls was larger than 2,000 in both target (East Asian)
and major (European descent) ethnic groups; the ethnic group-
specific OR was statistically significant (P,2.5610
23); and
heterogeneity in the ethnic group-specific OR between the target
and major ethnic groups was statistically significant (P,0.05).
Genetic risk models
We considered three logistic regression models: the HLA model
included the HLA-DRB1 alleles only; the non-HLA model
included the selected genetic variants at the non-HLA loci; and
the integrative model incorporated both of the HLA-DRB1 alleles
and the genetic variants at the non-HLA loci. In the logistic
regression analyses, the genetic risk score is as follows:




j~1 Zj logORj, ð1Þ
where Xi[ 0,1,2 fg is the number of risk alleles of SNP locus i,
X~ X1,:::,XL ðÞ is the genetic profiles of L loci genotypes,
Zj[ 0,1,2 fg is the indicator variable, indexing the number of each
of selected HLA-DRB1 alleles, Z~ Z1,:::,ZM ðÞ is the profiles
showing the subject’s HLA-DRB1 genotype, and the OR for each
variant is derived from the re-analysis of meta-analyses. The
integrative model was the full model that was expressed as the
equation [1], whereas the HLA and the non-HLA models were the
reduced models where the first and second terms on the right-
hand side of the equation [1] were excluded, respectively.
In order to assess the predictive ability of the models, we used
the ROC curve and calculated the AUC [16]. By definition, the
AUC is the probability that a randomly selected subject with the
disease of interest has a higher score than a randomly selected
subject without the disease. When the ROC analyses were
implemented, we restricted analyses to subjects with complete
genotype data. Thus, 1,231 cases and 1,445 controls were
available. We compared the fits of the three models with Akaike’s
information criterion.
Simulation study
In most common diseases, the predictive ability of common
genetic variants may be suboptimal at the current moment. We
therefore performed a simulation study to address how many
additional loci should be mapped to establish an acceptable level
of genetic risk prediction (AUC=80.0%).
We assumed two scenarios of allelic architecture of as-yet-
discovered genetic variants. First, we assumed the common
disease-common variant hypothesis, in which a large proportion
of the missing heritability can be explained by common variants
[107]. In this model, the per-allele OR was set to be 1.1 or 1.2 and
the RAF was set to be 0.1 or 0.3. Second, we assumed that the
multiple rare variants with intermediate effects remain undiscov-
ered [14]. In this model, we assumed that the per-allele OR was
2.0 or 3.0 with RAF of 0.01.
To simulate the distribution of RA risks in the general
population, we considered the constrained multiplicative model
[108]. First, we set ‘base model’, where all the possible com-
binations of genotypes of HLA-DRB1 alleles and selected SNPs
were included. For the base model, the ORs derived from our
case-control association study were used and the allele frequencies
in Japanese were obtained from SNP Control Database [106]
(shown in Text S1B). Next, we added N diallelic loci to the base
model. For simplicity, we assumed that the frequency and the
effect size of the risk allele at each additional locus are the same as
p and OR, respectively. We assumed that each locus is both in
HWE and in linkage equilibrium. We denote K as the prevalence
of RA and set it to 0.01. Under the rare disease assumption, the
relative risk can be approximated by the odds ratio. The risk and
the joint probability of multi-locus genotype can be written as the
product across loci:









k , and ð2Þ
p X,Z,W ðÞ ~PL




k~1 pW k ðÞ ,
respectively, where b is the background risk so that Eg ðÞ ~K,
pX i ðÞ is the probabilities of Xi, and W~ W1,:::,WN ðÞ is the genetic
profiles of N-locus genotypes with Wk[ 0,1,2 fg representing the
number of risk alleles of additional locus k. By the assumption that
each additional locus has the same p and OR, the equation [2] can
be written down as:






j ORs, and ð3Þ
p X,Z,W ðÞ ~PL









k~1Wk. For some genetic profiles with many risk
alleles, the risk expressed as the equation [3] can exceed 1. In the
constrained multiplicative model, if the risk exceeds 1, the risk is
set to 1 [108].
The probability of multi-locus genotype given disease status is:
p X,Z,WjDisease ðÞ ~g X,Z,W ðÞ |p X,Z,W ðÞ =
X
X,Z,W g X,Z,W ðÞ |p X,Z,W ðÞ , and
p X,Z,WjNonDisease ðÞ ~ p X,Z,W ðÞ { ½
K|p X,Z,WjDisease ðÞ   = 1{K ½  :
ð4Þ
For an arbitrary cut-off value of t, the true and false positive
rates are:
TPR t ðÞ ~
X
X,Z,W:g X,Z,W ðÞ §t p X,Z,WjDisease ðÞ , and
FPR t ðÞ ~
X
X,Z,W:g X,Z,W ðÞ §t p X,Z,WjNonDisease ðÞ ,
respectively:
Given the TPR and FPR at each cut-off value t, the ROC curve
can be drawn and then the AUC can be calculated by the
trapezoid rule [109].
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We assigned selected genetic variants to a single protein-coding
gene according to the following hierarchy: coding.intronic.59U-
TR.39UTR.near gene (within 2 kb to 59 or 0.5 kb to 39 of a
gene).intergenic. If a selected variant mapped an intergenic
region, we sought literature of fine-mapping studies or GWAS of
RA and other autoimmune diseases showing evidence of
association of variants in higher levels of the hierarchy.
The physical PPI network was constructed using the HPRD
database [75,76]. In PPI networks, vertices are proteins and edges
represent a physical interaction between two proteins. We
projected the RA-associated genes onto the constructed PPI
network and candidate genes were then ranked based on the
global distance to the RA-associated genes within the PPI network
by using random walk with restart (RWR) algorithm [77]. The
RWR algorithm is a powerful tool to measure proximity between
vertices on complex network.
In a random walk, starting at some initial ‘seed’ vertices (i.e.,
proteins encoded by the RA-associated genes), we chose at
random an edge that is attached to the current vertex and move
along the chosen edge to the linked vertex, and iterate many steps.
In the RWR, at each step of the walk we return to the initial seed
vertices with the restart probability, r. All vertices are ranked by
the number of times that the walker visits to corresponding vertices
in the process. The outline is described below.
The adjacency matrix A of the PPI network
is the matrix with elements Aij as follows:
Aij~




fine the transition probability matrix M so that the transition




(t) be a vector whose i-th element holds the probability of a
random walker being at vertex i at step t and p
(0) be the initial-state
probability vector, the probability vector at the step t+1i sa s
follows:
p tz1 ðÞ ~ 1{r ðÞ Mp t ðÞzrp 0 ðÞ :
In this study, p








The restart probability r was set to be 0.5. We considered the
random walker reached a steady-state when the difference between
p
(t+1) and p
(t) (measured by the L1 norm) reached 10
210. All the
genes in the PPI network were ranked according to the
corresponding values in the steady-state probability vector p
(‘).
The predictive ability of the network-guided prioritization of
genes was tested using leave-one-out cross-validation by omitting
each RA-associated gene in turn from initial ‘seed’ vertices and
performing the RWR algorithm for the purpose of its own
evaluation. The ROC curve was drawn by plotting the TPR
versus the FPR for all genes ranked above a sliding ranking
threshold.
We define RA-associated network as a subnetwork in which
vertices are the RA-associated genes and genes ranked in the top
100 by the RWR algorithm and edges are physical interactions
between their products. Functional modules are then explored in
the RA-associated network. The overlapping and hierarchical
clusters were detected by using the EAGLE algorithm [84]. The
functional annotation for the retrieved clusters was performed by
using DAVID [85,86]. We set 9,521 genes on the PPI network
from HPRD as the background in enrichment analysis.
Supporting Information
Figure S1 Flowchart detailing the exclusion and inclu-
sion criteria and the number of studies excluded and
included at each step of the electronic database
searches. A) PubMed, and B) NHGRI GWAS catalog.
(TIF)
Figure S2 RA-associated network comprising known
RA-associated genes and genes ranked in the top 50 by
the RWR algorithm and edges are physical interactions
between their products. Nodes are color coded by hierarchical
clusters detected by the EAGLE algorithm: CL1, red; CL2; cyan,
and CL3, yellow. Overlapped regions between CL1 and CL2 are
rendered in green. Node size is based on the ranking in the RWR
algorithm.
(TIF)
Figure S3 RA-associated network comprising known
RA-associated genes and genes ranked in the top 150 by
the RWR algorithm and edges are physical interactions
between their products. Nodes are color coded by hierarchical
clusters detected by the EAGLE algorithm: CL1, red; CL2; cyan,
CL3, yellow; and CL4, orange. Overlapped regions between CL1
and CL2, CL1 and CL4, and CL2 and CL4 are rendered in green,
pink, and purple, respectively. Node size is based on the ranking in
the RWR algorithm.
(TIF)
Figure S4 Re-consideration on RA-associated network.
The RWR algorithm was re-examined by adding recently
discovered 4 genes (AIRE, CD247, UBASH3A, and ATXN2). Nodes
are color coded by hierarchical clusters detected by the EAGLE
algorithm: CL1, red; CL2; cyan, and CL3, yellow. Overlapped
regions between CL1 and CL2 are rendered in green. Node size is
based on the ranking in the RWR algorithm.
(TIFF)
Table S1 Result of ratings for 87 abstracts retrieved
from PubMed. The scoring was conducted by independent two
authors (Hirofumi Nakaoka and Tailin Cui), which is color-coded
in green and blue, respectively. Any disagreement between the two
researchers was accommodated by Atsushi Tajima. The final
decision is rendered in red.
(DOC)
Table S2 Result of rating for 54 full-text articles.
(DOC)
Table S3 Result of screening of extracted data from 51
full-text articles.
(DOC)
Table S4 Re-analysis of meta-analyses addressing ge-
netic associations with RA risk.
(DOC)
Table S5 Assignment of a single gene to genetic variants
associated with RA and the allele frequencies in
European and Japanese.
(DOC)
Table S6 Ethnic group-specific analysis of published
meta-analyses of genetic associations with RA risk. The
SNPs in which the heterogeneity in the ORs between European
and East Asian populations are significant are highlighted in
yellow.
(DOC)
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15 SNPs.
(DOC)
Table S8 Association analysis of RF and anti-CCP
positive RA patients versus control subjects with
selected genetic variants.
(DOC)
Table S9 GO and KEGG annotations for three clusters
in RA-associated network comprising RA-associated
genes and genes ranked in the top 50 by the RWR
algorithm.
(DOC)
Table S10 GO and KEGG annotations for three clusters
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